How to Engage T Cell in Myeloma

Basic Information

Funding Cycle : 2022-2023
Name : Marc Raab
Type of Award : Translational Research Award
Home Institution : German Cancer Research Center (DKFZ), Germany


The project aims to analyze tumor-infiltrating lymphocytes (TILs) in multiple myeloma patients treated with bispecific T-cell engager (bsAb) therapy, utilizing single-cell analyses to understand T-cell diversity, phenotype dynamics, and specificity. By correlating sequencing data with functional validation of anti-tumor reactivity, the study seeks to predict response to bsAb therapy. This integrated approach, combining clinical expertise from a leading myeloma center with bioinformatics infrastructure, aims to elucidate the immunological mechanisms of bsAb therapy and contribute to overcoming challenges in identifying and monitoring T-cell responses against various tumors. Ultimately, the project aims to develop a workflow for predicting bsAb therapy response, potentially advancing immunotherapy strategies for myeloma and other cancers.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events